- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Disease and Diabetes
The Practical Cardiology™ Heart Disease and Diabetes clinical resource center offers readers the latest in the field of diabetes and cardiovascular disease. With the field of cardiometabolic health becoming a focal point in the fight against cardiovascular disease, this page will host content related to the latest FDA approvals, studies, guideline update, and clinical perspectives from advisory board members.
Top New Trial Data at ESC Congress 2022
September 03, 2022
Although the European Society of Cardiology (ESC) Congress 2022 may be over, our editorial team is recapping the most popular new trial data from the ESC’s first in-person conference since 2019. The top 5 trials, which were chosen based on total views per article, includes DELIVER, TIME, AXIOMATIC-SSP, FIDELITY, and DANCAVAS.
In Patients with Cancer and Diabetes, SGLT2 Inhibitors Could Provide Cardioprotection Against Anthracyclines
August 24, 2022
An analysis of patients treated in the Massachusetts General Brigham hospital system provides into the potential cardioprotective benefits of SGLT2 inhibitor use among patients with diabetes and cancer receiving treatment with anthracyclines.
Study Warns of Significant Increases in Diabetes and Cardiovascular Disease by 2060
August 01, 2022
Using data from the 2020 US Census report and recent NHANES survey data, investigators from Massachusetts General Hospital detail expected increases in the prevalence of cardiovascular risk factors and cardiovascular disease among the US population by 2060.
Dapagliflozin's Cardiorenal Benefits Consistent in T2D, Regardless of Background CV Medication Use
July 20, 2022
A secondary analysis of the DECLARE-TIMI 58 trial details the cardiorenal protective benefits of dapagliflozin across subgroups of patients defined by use of background cardiovascular medication use.
Medicare Advantage Beneficiaries Less Likely to Receive GLP-1 RA and SGLT2 Inhibitor Prescriptions
July 14, 2022
A comparison of data from more than 340,000 Medicare beneficiaries with diabetes provides insight into the real-world differences in the management of these patients, including disparities in the prescription of GLP-1 RAs and SGLT2 inhibitors.
Prediabetes Not as Benign as Once Believed, Associated with Increased Risk of Heart Attacks
June 17, 2022
An analysis of the National Inpatient Sample details the statistically significant increases in the risk of experiencing myocardial infarction, PCI, or CABG in patients with prediabetes compared to their normoglycemic counterparts.
Exploring Racial/Ethnic Disparities in Arterial Stiffness in Youth with Type 1 Diabetes
June 07, 2022
Katherine Sauder, PhD, provides perspective on an ADA 2022 study she led examining racial/ethnic disparities in arterial stiffness among youths with type 1 diabetes in the US.
Empagliflozin Provides Greater HF Risk Reduction than Other Glucose-Lowering Agents
June 06, 2022
A 5-year monitoring program, data from the EMPRISE study detail the comparative risk reductions provided by empagliflozin against GLP-1 RAs or DPP-4 inhibitors for heart failure hospitalizations.
No Red Flags for Fracture Risk with SGLT2 Inhibitors in Diabetic Kidney Disease
May 31, 2022
An analysis of data from more than 75,000 patients with diabetic kidney disease details the risk of fracture among new users of SGLT2 inhibitors compared to new users of DPP-4 inhibitors.
Metformin, Lifestyle Changes Not Enough to Stave off CVD Risk in T2D
May 27, 2022
Data from an analysis of follow-up data from the landmark DPPOS study provide insight into the apparent lack of cardiovascular risk reduction provided to patients with prediabetes from metformin and lifestyle interventions.